AN2 Therapeutics to Participate in Fireside Chat at Leerink Global Healthcare Conference

AN2 Therapeutics, Inc. (Nasdaq: ANTX), a biopharmaceutical company specializing in small molecule therapeutics developed from a unique boron chemistry platform, has announced that Eric Easom, Co-Founder, Chairman, President, and CEO, will take part in a fireside chat at the upcoming Leerink Global Healthcare Conference. The event is scheduled for March 10, 2026, at 3:40 PM ET. Investors and interested parties can access a live webcast of the discussion through the Investors section of the AN2 Therapeutics website, with an archived replay available for at least 30 days afterward.

AN2 Therapeutics is dedicated to advancing its pipeline of boron-based compounds targeting significant health challenges, including Chagas disease, non-tuberculous mycobacterial (NTM) lung disease caused by Mycobacterium abscessus, and melioidosis. The company is also engaged in developing therapies aimed at cancer and various infectious diseases. With a commitment to addressing critical unmet medical needs, AN2 Therapeutics aspires to enhance health outcomes through its innovative drug development approach.

For more information about AN2 Therapeutics and its ongoing projects, visit the official website at www.an2therapeutics.com. The fireside chat at the Leerink Global Healthcare Conference represents an opportunity for the company to share its vision and progress with potential investors and the broader healthcare community.

For inquiries, the company's Chief Financial Officer, Lucy O. Day can be reached via email, and investor relations contact Anne Bowdidge is also available for media interactions. This participation underscores AN2 Therapeutics' ongoing commitment to innovation in the biopharmaceutical sector and its engagement with investors in the healthcare space.

AN2 Therapeutics, Inc. (Nasdaq: ANTX) stands out in the biopharmaceutical sector due to its innovative approach in utilizing boron chemistry to develop small molecule therapeutics targeting significant health challenges like Chagas disease and NTM lung disease. The company's participation in the upcoming Leerink Global Healthcare Conference on March 10, 2026, provides a valuable opportunity for investors to gain insights into its strategic direction and scientific advancements.

As the biopharmaceutical landscape continues to evolve, AN2’s unique pipeline presents a compelling narrative. Investors should note that the successful development of its boron-based compounds could have profound implications, not only for public health but also for the company’s market valuation. Given the critical unmet needs in the diseases AN2 targets, if these compounds pass through development hurdles, they could see expedited approval pathways, potentially increasing their market relevance and commercial viability.

Participation in a prominent conference like this allows AN2's leadership to engage directly with analysts and investors, sharing insights into their clinical programs and overall vision, which is crucial for building investor confidence. Monitoring the market reaction to the fireside chat could provide vital indicators of investor sentiment. Should the conversation lean positively toward the therapeutic pipeline or potential partnerships, this might trigger a stock uptick.

It's essential for investors to keep an eye on the data released during the conference and subsequent developments from AN2 before making decisions. Furthermore, with the stock trading on Nasdaq, related market movements can also be indicative of broader investor appetites for biopharmaceutical equities. As such, potential investors may want to approach with a discerning eye, considering both the product pipeline quality and broader industry trends in the biopharmaceutical domain.